Name: Latest research reports of Divi's Laboratories Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Divi's Laboratories Ltd.
Rating: 1
Author: BOB Capital Markets Ltd.

Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer

6132.5000 32.00 (0.52%)

NSE Aug 14, 2025 15:31 PM

32.87% Gain from 52W Low

Volume: 407.1K

Divi's Laboratories Ltd.

25 May 2024

6132.50

0.52%

Divi's Labs (SELL): Strong quarter; rich valuations

Sell: Divi's Laboratories Ltd.

BOB Capital Markets Ltd.

DIVI delivered a strong quarter with all round beat. EBITDA/PAT beat Bloomberg consensus estimate by 20% each

Divi's Laboratories .. has an average target of 6447.40 from 5 brokers.